
Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
Author(s) -
I.C. Nogueira Costa,
Jorge Reis,
Sara Meireles,
Maria João Marques Ribeiro,
I. Augusto,
M. Barbosa
Publication year - 2022
Publication title -
european journal of case reports in internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2284-2594
DOI - 10.12890/2022_003331
Subject(s) - olaparib , carboplatin , medicine , prostate cancer , parp inhibitor , oncology , brca2 protein , malignancy , synthetic lethality , prostate , poly adp ribose polymerase , cancer , cancer research , chemotherapy , mutation , docetaxel , cisplatin , dna repair , gene , genetics , germline mutation , biology , polymerase